Published • loading... • Updated
New 250 mg cancer drug generic DT-CRZ enters trial stage in Moscow
Summary by Правда.Ру
Read with caution - this story is only being covered by one news source that has a ‘low factuality’ rating, which means the outlet has a history of poor reporting practices. Learn more about factuality ratings here.1 Articles
1 Articles
New 250 mg cancer drug generic DT-CRZ enters trial stage in Moscow
Russia has launched clinical trials for DT-CRZ, a domestic generic version of the cancer drug Xalkori (active ingredient: crizotinib). The studies aim to evaluate pharmacokinetics and confirm bioequivalence for the new medication, which is produced in 250 mg capsule form. The trials are being conducted at the Research Lab center in Moscow. Up to 90 volunteers will participate in the study. The Ministry of Health of the Russian Federation has aut…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right1Center0Last UpdatedBias Distribution100% Right
Bias Distribution
- 100% of the sources lean Right
100% Right
R 100%
Factuality
To view factuality data please Upgrade to Premium
